Join our daily newsletter At The Bell to receive exclusive market insights
- Proteomics has secured CE Mark registration for its kidney disease test, PromarkerD
- Promarker D is a simple blood test that uses a uniques protein ‘fingerprint’ to detect the disease up to four years before clinical symptoms appear
- This announcement follows the launch of PromarkerD in Spain, where diabetes affects 10 per cent of the adult population
- Proteomics is up 1.49 per cent on the ASX and is selling shares for 34 cents apiece
Proteomics International Laboratories has secured CE Mark registration for its PromarkerD as a diagnostic medical device.
PromarkerD is a world-first test for predicting the beginning of diabetic kidney disease.
CE marking is a certification mark that indicates a fitting in with health, safety and environmental protection standards for products sold within the European Economic Area.
The test assesses the risk of diabetic kidney disease in patients with type 2 diabetes. Chronic kidney disease is one of the major complications that can come from diabetes and if unchecked can lead to dialysis or a kidney transplant.
Promarker D is a simple blood test that uses a unique protein ‘fingerprint’ to detect the disease up to four years before clinical symptoms appear.
“The CE Mark is another important milestone for PromarkerD as we move forward with new deals in the region,” Managing Director Richard Lipscombe said.
“CE Mark registration reflects the strength of the clinical and technical data that we have collected in developing our ground-breaking test that could help save healthcare systems billions of dollars,” he added.
This announcement follows the launch of PromarkerD in Spain, where diabetes affects 10 per cent of the adult population (3.6 million people).
The World Health Organisation believes that the European Region is home to 60 million adults with diabetes and currently 1 in 3 have chronic kidney disease.
“PromarkerD could aid clinical decision-making by identifying at-risk individuals for earlier therapeutic intervention and help to minimise the effect of the disease,” the company stated.
Proteomics is up 1.49 per cent on the Australian Securities Exchange and is selling shares for 34 cents apiece at 12:55 pm AEDT.
